- ASSISTANT PROFESSOR Medicine, Cardiology
American Board of Internal Medicine
- General Cardiology
- Hyperlipidemia/High Cholesterol
- Type 2 Diabetes
MD, Seth GS Medical College and KEM Hospital
Residency, Internal Medicine
Wyckhoff Heights Medical Center
Mount Sinai Hospital
Sameer Bansilal, MD, MS earned his medical degree from University of Mumbai, India, completed his residency training in Internal Medicine at New York Methodist Hospital, and clinical cardiology fellowship at Mount Sinai Hospital. He has completed post-doctoral research fellowships at the TIMI Study Group at Brigham and Women’s Hospital in Boston, and at Mount Sinai. He holds a Masters in Clinical Research from the Mount Sinai-NYU Program and has completed the Program in Clinical Effectiveness at the Harvard School of Public Health.
He has served as a key member of multiple mega-trials such as FREEDOM, PEGASUS-TIMI 54 and DECLARE-TIMI 58. Currently he is the medical lead for the Grenada Heart Project, the American Heart Association Prevention Center at Mount Sinai and the Polypill Program in the U.S.
Dr. Bansilal's research interests include evaluation of innovative strategies and therapies for coronary disease and diabetes in global populations. His special interests include advanced trial design and trial methodology.
Dr. Bansilal is certified by the American Board of Internal Medicine in both Cardiovascular Disease and Internal Medicine, and he is also Board Certified in Nuclear Cardiology. He is a long-standing member of the American Heart Association, and the American College of Cardiology. He is an Associate Editor of the journal Global Heart, and Assistant Editor for the Journal of the American College of Cardiology.
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V. Strategies for multivessel revascularization in patients with diabetes. The New England journal of medicine 2012 Dec; 367(25).
Bansilal S, Farkouh ME, Hueb W, Ogdie M, Dangas G, Lansky AJ, Cohen DJ, Magnuson EA, Ramanathan K, Tanguay JF, Muratov V, Sleeper LA, Domanski M, Bertrand ME, Fuster V. The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry. American heart journal 2012 Oct; 164(4).
Fuster V, Bansilal S. Promoting cardiovascular and cerebrovascular health. Stroke; a journal of cerebral circulation 2010 Jun; 41(6).
Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, Guzmán L, Linares JC, García F, D'Aniello F, Arnáiz JA, Varea S, Martínez F, Lorenzatti A, Imaz I, Sánchez-Gómez LM, Roncaglioni MC, Baviera M, Smith SC, Taubert K, Pocock S, Brotons C, Farkouh ME, Fuster V. A Polypill Strategy to Improve Adherence: Results From the FOCUS Project. Journal of the American College of Cardiology 2014 Sep;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Bansilal has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor MC LEVEL Room FREEDOM OFFICE
1425 Madison Avenue
New York, NY 10029
1190 Fifth Avenue
New York, NY 10029